Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 7/20 | 0.54 |
| ▸ | CTSK | P43235 | 6/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | PPARA | Q07869 | 5/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 4/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864800 | 1.00 | PTPN1 (0.54) | PTPN1CTSSCTSKACEPPARA | |
| SCHEMBL30765042 | 1.00 | PTPN1 (0.54) | PTPN1CTSSCTSKACEPPARA | |
| SCHEMBL30765047 | 0.89 | CTSS (0.50) | PTPN1CTSSCTSKACESCN9A | |
| SCHEMBL30765049 | 0.89 | CTSS (0.50) | PTPN1CTSSCTSKACESCN9A | |
| SCHEMBL2894889 | 0.89 | CTSS (0.50) | PTPN1CTSSCTSKACESCN9A | |
| SCHEMBL2898437 | 0.89 | CTSS (0.50) | PTPN1CTSSCTSKACESCN9A | |
| SCHEMBL5845049 | 0.89 | CTSS (0.55) | PTPN1CTSSCTSKACEPPARA | |
| SCHEMBL5845045 | 0.89 | CTSS (0.55) | PTPN1CTSSCTSKACEPPARA | |
| SCHEMBL5318364 | 0.89 | CTSS (0.55) | PTPN1CTSSCTSKACEPPARA | |
| SCHEMBL30461851 | 0.89 | CTSS (0.55) | PTPN1CTSSCTSKACEPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067665-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | AVIKO RADIOPHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067665-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | AVIKO RADIOPHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067665-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | AVIKO RADIOPHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2024035871-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | AVIKO RADIOPHARMACEUTICALS, LLC (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| EP-2406247-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| WO-2010103333-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103333-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| WO-2009034388-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, DPP4, DPP9 | PTPN1 2545/4885CTSS 1847/4885CTSK 1525/4885 |
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | PTPN1 3970/4885CTSS 2448/4885CTSK 2018/4885 |
| US-20240067665-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | NME2, BTD, BLVRB | PTPN1 3566/4885CTSS 1784/4885CTSK 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.